RxDoctor Payments Data

Minesh Khatri, MD

Nephrology · Mineola, NYNPI 1407056468

Payments from drug & device makers

$9,697in general payments, 2019–2025

Across 18 payments — averaging $538.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$9K
  • AstraZeneca$308
  • Apellis Pharmaceuticals, Inc.$97
  • Novartis$23
  • Amgen$20
  • Bayer$16

What the payments were for

  • Consulting fees$8,10084%
  • Travel & lodging$6517%
  • Food & beverage$94610%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Travere Therapeutics, Inc.11$9,232
AstraZeneca(2 entities)3$308
Apellis Pharmaceuticals, Inc.1$97
Novartis1$23
Amgen1$20
Bayer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,697 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$282,856
Medicare patients
576
Services billed
4,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol101$113,011
KerendiaFinerenone34$40,733
JardianceEmpagliflozin30$39,285
LokelmaSodium Zirconium Cyclosilicate40$38,184
EntrestoSacubitril/Valsartan17$19,064
VeltassaPatiromer Calcium Sorbitex16$15,114
Eplerenone58$9,025
Mycophenolic AcidMycophenolate Sodium12$6,697
Sevelamer Carbonate29$5,935
Tacrolimus13$2,477
Torsemide80$2,277
Nifedipine ErNifedipine17$1,205
Calcitriol65$976
Losartan Potassium99$969
Potassium Citrate ErPotassium Citrate13$941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$308$151,195141 claims
BayerKerendia$16$40,73334 claims
NovartisEntresto$23$19,06417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.

Other nephrology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →